MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1055/s-0041-1726366

Медицинская библиотека · The International journal of angiology : official publication of the International College of Angiology, Inc · 2021

Sequential Use of Romiplostim after Eltrombopag for Refractory Thrombocytopenia in Hydrocarbon-Induced Myelodysplasia.

Morales Luis F, Miyara Santiago J, Guevara Sara, Metz Christine N, Shoaib Muhammad, Watt Stacey, Zafeiropoulos Stefanos, McCann-Molmenti Alexia, Hayashida Kei, Takegawa Ryosuke, Shinozaki Koichiro, Choudhary Rishabh C, Brindley Elena C, Nishikimi Mitsuaki, Kressel Adam M, Alsalmay Yaser M, Mazzotta Elvio A, Cho Young Min, Aranalde Gabriel I, Grande Daniel A, Zanos Stavros, Shore-Lesserson Linda, Becker Lance B, Molmenti Ernesto P

СтатьяПеревод в очереди

Аннотация

We describe the clinical course of a 65-year-old male patient who suffered from hydrocarbon-induced myelodysplasia and was successfully treated with the thrombopoietin receptor agonist (TPO-RA), romiplostim. Myelodysplastic syndromes (MDS) are characterized by ineffective hematopoiesis, cytopenias, and increased risk of leukemic transformation. Here, we present a clinical vignette of MDS-associated thrombocytopenia refractory to first-line drugs as well as the TPO-RA, eltrombopag. To date, romiplostim is an U.S. Food and Drug Administration (FDA)-approved drug for idiopathic thrombocytopenic purpura and thrombocytopenia secondary to liver disease. Of note, currently the FDA advises against its use in MDS based on previous long-term safety concerns. Since the therapeutic options for thrombocytopenia in MDS patients are sparse, repurposing and reassessing romiplostim in this setting have been the focus of recent studies. At the time of writing, no published double-blind randomized clinical trials have conducted a head-to-head comparison between romiplostim and eltrombopag in thrombocytopenic MDS patients. To the best of our knowledge, for a thrombocytopenic patient in the setting of MDS, this is the first documented report of refractory clinical response after a 2-year use of eltrombopag in which replacement of treatment with romiplostim resulted in sustained physiological counts of thrombocytes within four weeks.

Для цитирования: Morales Luis F, Miyara Santiago J, Guevara Sara, Metz Christine N, Shoaib Muhammad, Watt Stacey, Zafeiropoulos Stefanos, McCann-Molmenti Alexia, Hayashida Kei, Takegawa Ryosuke, Shinozaki Koichiro, Choudhary Rishabh C, Brindley Elena C, Nishikimi Mitsuaki, Kressel Adam M, Alsalmay Yaser M, Mazzotta Elvio A, Cho Young Min, Aranalde Gabriel I, Grande Daniel A, Zanos Stavros, Shore-Lesserson Linda, Becker Lance B, Molmenti Ernesto P. Sequential Use of Romiplostim after Eltrombopag for Refractory Thrombocytopenia in Hydrocarbon-Induced Myelodysplasia.. The International journal of angiology : official publication of the International College of Angiology, Inc. 2021. DOI: 10.1055/s-0041-1726366.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.